Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 18, 2023

Real-World Outcomes of Women With HER2-Positive Early Breast Cancer Receiving Adjuvant Trastuzumab

Scientific Reports


Additional Info

Scientific Reports
Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
Sci Rep 2023 May 03;13(1)7168, J Lluch-Gómez, V Núñez-Álvarez, C de la Torre-Hita, M Bernal-Gómez, A Campini-Bermejo, E Perdomo-Zaldívar, L Rodríguez-Pérez, J Calvete-Candenas, MJ Martínez-Bautista, E Benítez-Rodríguez, JM Baena-Cañada

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading